natgillin/translations-raw huggingface dataset:
Disse omfatter sepsis (blodforgiftning), meningitis (infektion af membranerne omkring hjernen og rygmarven), lungebetændelse, mellemørebetændelse og bakteriæmi (bakterier i blodet).
These include sepsis (blood infection), meningitis (infection of the membranes that surround the brain and spine), pneumonia (infection of the lungs), otitis media (infection of the middle ear) and bacteraemia (bacteria detected in the blood).
Disse omfatter visse antibiotika (Bactrim og Septra, som begge er en kombination af sulfamethoxazol og trimetoprim), som bruges ved behandling af infektioner.
These include some antibiotics (Bactrim and Septra used in combination of sulfamethoxazole and trimethoprim), which can be used to treat infections
Disse omfatter:
These include patients:
Disse omfatter:
These may include:
Disse omfatter: medicin mod HIV-infektion (såsom ritonavir, nelfinavir, amprenavir eller fosamprenavir)
These include: medicines for HIV infection (such as ritonavir, nelfinavir, amprenavir or fosamprenavir)
Disse omfatter: muskelsmerter, -ømhed eller svaghed.
These are: muscle pain, tenderness or weakness.
Disse opkastninger skyldes sandsynligvis en lokal virkning på tyndtarmen.
This vomiting is most likely caused by a local effect on the small intestines.
Disse oplysninger er ment som vejledning til sundhedspersonale i tilfælde af, at produktet midlertidigt har været opbevaret uden for køleskab
These data are intended to guide health care professionals in case of temporary temperature excursions.
Disse oplysninger kan ikke erstatte samtaler med din læge eller sygeplejerske om din sygdom eller din behandling.
This information does not replace talking to your doctor or nurse about your medical condition or your treatment.
Disse oplysninger kommer fra et register, og virksomheden vil nærmere granske, hvad der sker med lægemidlet i kroppen, især hos børn.
This information comes from a registry and will further investigate what happens to the medicine in the body, especially in children.
Disse parametre genoprettes til normal indenfor 1 uge efter den sidste injektion. forbigående træthed i løbet af behandlingen, kun hos katte.
These parameters return to normal in the week following the last injection. transient fatigue during the treatment, in cats only.
Disse parametre stemte overens med den lineære dosis farmakokinetik over et bredt dosisinterval (0,5 til 8 g/kg ugentlig og 3 til 9 g/kg hver anden uge).
These parameters were consistent with dose linear pharmacokinetics over a wide dose range (0.5 to 8 µg/kg weekly and 3 to 9 µg/kg every two weeks).
Disse partielle anfald kan sprede og udvide sig til større områder i begge sider af hjernen – dette kaldes en ”sekundær generalisering”.
These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a ‘secondary generalisation’.
Disse partikler har ingen betydning for produktets kvalitet.
The presence of these particles does not affect the quality of the product.
Disse patient-rapporterede resultater var i høj grad korreleret til klinikerens graduering af oral mucositis efter WHO skalaen.
These patient-reported outcomes were highly correlated to the clinician grading of oral mucositis using the WHO scale.
Disse patienter blev klassificeret som uge-2 responderende og blev inkluderet i den primæ re analyse (se tabel 5).
These patients were classified as week-2 responders and were included in the primary analysis (see Table 5).
Disse patienter blev klassificeret som uge-2 responderende og blev inkluderet i den primære analyse (se tabel 5).
Week-14 responders (195/282) were analysed for the primary endpoint, which was time from randomisation to loss of response (see Table 7).
Disse patienter blev sammenlignet med en ”historisk sammenligningsgruppe” af spædbørn og små børn med Pompes sygdom, som ikke havde modtaget behandling og ikke deltog i undersøgelserne.
These patients were compared with a ‘historical comparison group’ of babies and young children with Pompe disease who had not received treatment and did not take part in the studies.
Disse patienter bør derfor overvåges nøje under indgivelse af Myozyme.
Therefore, these patients should be monitored more closely during administration of Myozyme.
Disse patienter bør henvises til en kardiolog til kontrol og opfølgning.
All such patients should be referred for assessment by a cardiologist and followed up.
Disse patienter bør monitoreres for tegn og symptomer på aktiv HBV- infektion gennem hele behandlingsforløbet og i flere uger efter, at behandlingen er afsluttet.
These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy.
Disse patienter bør monitoreres omhyggeligt for kliniske tegn og symptomer på CHF, især hvis de har hjerte-risikofaktorer og/eller arteriel sygdom i anamnesen.
Close monitoring for clinical signs and symptoms of CHF should be performed, especially in patients with cardiac risk factors and/or history of coronary artery disease.
Disse patienter bør monitoreres omhyggeligt for kliniske tegn og symptomer på CHF, mens de får sunitinib.
These patients should be carefully monitored for clinical signs and symptoms of CHF while receiving sunitinib.
Disse patienter bør observeres nøje for tegn og symptomer på tromboemboli.
These patients should be observed carefully for signs and symptoms of thromboembolism.
Disse patienter bør starte med en lavere dosis, som gives hver anden dag.
These patients should be started at a lower dose which should be given every other day.
Disse patienter er i kliniske studier blevet identificeret med et endogent LH–serum-niveau på <1,2 IE/l.
In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.
Disse patienter er i kliniske studier blevet identificeret med et endogent LH–serumniveau på < 1,2 IE/l.
In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.
Disse patienter fik darunavir 800 mg en gang dagligt i kombination med cobicistat 150 mg en gang dagligt med et investigatorvalgt baggrundsregime bestående af 2 aktive NRTI’er.
These patients received darunavir 800 mg once daily in combination with cobicistat 150 mg once daily with an investigator selected background regimen consisting of 2 active NRTIs.
Disse patienter fik Glivec i en periode varierende mellem 24 dage og 60 måneder (median 47 måneder).
These patients received Glivec for a median of 47 months (range 24 days – 60 months).
Disse patienter fik imatinib i en periode varierende mellem 24 dage og 60 måneder (median 47 måneder).
These patients received imatinib for a median of 47 months (range 24 days – 60 months).
Disse patienter fik Imatinib Teva i en periode varierende mellem 24 dage og 60 måneder (median 47 måneder).
These patients received imatinib for a median of 47 months (range 24 days – 60 months).
Disse patienter har begrænsede behandlingsmuligheder, og Darzalex, der virker på en anden måde end de øvrige behandlinger, kan være et alternativ.
These patients have limited treatment options and Darzalex, which works in a different way to existing treatments, represents an alternative.
Disse patienter har sædvanligvis et dårligt forløb, men i gennemsnit blev sygdommens fremskriden forsinket med 6,9 måneder, hvilket kan gøre det muligt at udskyde næste behandlingsserie med platinbaseret kemoterapi.
These patients, who generally have poor prognosis, experienced an overall delay of 6.9 months in the progression of their disease, which might allow the next cycle of platinum-based chemotherapy to be delayed.
Disse patienter havde en høj sygdomsaktivitet, defineret som forhøjet hæmolyse (LDH ≥ 1,5 x ULN) og tilstedeværelse af et eller flere tilknyttede kliniske symptomer som træthed, hæmoglobinuri, abdominalsmerter, dyspnø, anæmi (hæmoglobin < 100 g/l), alvorlig vaskulær bivirkning (inklusive trombose), dysfagi eller erektil dysfunktion.
These patients had high disease activity as defined by elevated haemolysis (LDH ≥1.5x ULN) and the presence of related clinical symptom(s): fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin <100 g/L), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.
Disse patienter havde mange forskellige komplekse underliggende sygdomme, såsom maligne hæmatologiske sygdomme og HIV-infektion, eller var transplanterede og/eller fik intensiv behandling.
These patients had a wide variety of complex underlying conditions such as haematological malignancies and HIV-infection or were transplant recipients and/or treated in intensive care.
Disse patienter havde stabil hiv-sygdom og gennemsnittet af CD4 T- celletal var omkring 500 celler/µl.
These patients had stable HIV disease and mean CD4 T-cell count was about 500 cells/µl.
Disse patienter kan have behov for højere doser end patienter med andre typer af von Willebrands sygdom for at opretholde et tilstrækkeligt niveau.
3 VWD where maintenance of adequate levels may require greater doses than in other types of VWD.
Disse patienter levede gennemsnitligt 11,2 måneder, uden at deres sygdom forværredes.
These patients lived for an average of 11.2 months without their disease getting worse.
Disse patienter skal følges tæt.
These patients should be followed closely.
Disse patienter var i aldersgruppen 18–83 år og havde en patologisk diagnose af Kit-positiv malignt GIST, der var inoperabelt og/eller metastaserende.
These patients ranged in age from 18 to 83 years old and had a pathologic diagnosis of Kit-positive malignant GIST that was unresectable and/or metastatic.
Disse patienter vil også modtage et advarselskort, som de altid skal bære på sig, med instruktioner om at kontakte deres læge øjeblikkeligt, hvis de oplever symptomer på infektion.
These patients are also to receive an alert card, which they are to carry at all times, instructing them to contact their doctor immediately if they experience symptoms of infection.
Disse patienters HR for PFS og OS var henholdsvis 1,24 (95 % CI: 0,68; 2,28) og 1,09 (95 % CI: 0,70; 1,70).
The HR for these patients for PFS and OS was 1.24 (95% CI: 0.68, 2.28) and 1.09 (95% CI: 0.70, 1.70), respectively.
Disse patientobserverede forskelle blev set allerede 8 uger efter påbegyndelse af behandling.
These patient- observable differences were seen 8 weeks after initiating treatment.
Disse penne er kun beregnet til en person.
These pens are only for one person.
Disse personer havde en Cmax koncentration, der var omkring 3 gange højere ved cirka 7 timer og havde en halveringstid i terminalfasen på cirka 89 timer.
These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.
Disse pile  viser den retning, du skal trække eller dreje doseringsknappen i til det næste trin.
These arrows  show the direction to pull or turn the dose knob in the next step.
Disse poser må ikke fjernes fra glasset og må ikke spises.
These pouches should stay in the bottle all the time and are not to be eaten.
Disse protonerede aminer binder negativt ladede ioner, som f.eks. phosphat fra maden, i tarmen.
These protonated amines bind negatively charged ions such as dietary phosphate in the intestine.
Disse protonerede aminer binder negativt ladede ioner, som fx phosphat fra maden, i tarmen.
These protonated amines bind negatively charged ions such as dietary phosphate in the intestine.
Disse præparater kan øge risikoen for blødning.
They may increase the risk of bleeding.
Disse prøver af udåndingsluft anvendes til at måle det naturlige niveau af 13C i udåndingsluftens kuldioxid.
These breath samples are used to measure the natural level of 13C in the carbon dioxide of the breath.
Disse prøver vil blive analyseret for at måle den normale mængde af 13C i Deres udåndede kuldioxid.
These samples will be analysed to measure the normal amount of 13C in the carbon dioxide in your breath.
Disse punkter skal overvejes ved initiering af pramipexol behandling hos patienter med Parkinsons sygdom.
These points should be considered when initiating pramipexole treatment in patients with Parkinson’s disease.
Disse punkter skal overvejes ved initiering af pramipexolbehandling hos patienter med Parkinsons sygdom.
These points should be considered when initiating pramipexole treatment in patients with Parkinson’s disease.
Disse påvirkninger er langt mindre tilbøjelige til at forekomme i forbindelse med inhalationsbehandling, end med oral behandling.
These effects are much less likely to occur with inhalation treatment than with oral corticosteroids.
Disse rapporter omfatter nedsat synsskarphed, sløret syn, fotopsi, synsfeltsdefekt, nedsat syn, tørre øjne, øjenlågsødem, blepharospasme, øjensmerter og hævelse af øjet.
These reports include visual acuity reduced, blurred vision, photopsia, visual field defect, visual impairment, dry eye, eyelid oedema, blepharospasm, eye pain and eye swelling.
Disse reaktioner begynder inden for 24- 72 timer efter vaccination, kan sammenknyttes med rødme, varme, ømhed eller smerte på injektionsstedet og bliver bedre inden for 3-5 dage uden behov for behandling. kramper med eller uden feber
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever
Disse reaktioner begynder inden for 24- 72 timer efter vaccination, kan sammenknyttes med rødme, varme, ømhed eller smerte på injektionsstedet og bliver bedre inden for 3-5 dage uden behov for behandling. kramper med eller uden feber.
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever.
Disse reaktioner begynder inden for 24-72 timer efter vaccination, kan sammenknyttes med rødme, varme, ømhed eller smerte på injektionsstedet og bliver bedre inden for 3-5 dage uden behov for behandling. kramper med eller uden feber
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever
Disse reaktioner begynder inden for 24-72 timer efter vaccination, kan sammenknyttes med rødme, varme, ømhed eller smerte på injektionsstedet og bliver bedre inden for 3-5 dage uden behov for behandling. kramper med eller uden feber.
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever.
Disse reaktioner blev beskrevet under brug af NCI Common Toxicity Criteria (grad 3 = G3; grad 3- 4 = G3/4; grad 4 = G4), COSTART-termerne og MEdDRA-termerne.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Disse reaktioner blev beskrevet under brug af NCI Common Toxicity Criteria (grad 3 = G3; grad 3- 4 = G3/4; grad 4 = G4), COSTART-termerne og MEdDRA-termerne..
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4), the COSTART and the MedDRA terms.
Disse reaktioner blev beskrevet under brug af NCI Common Toxicity Criteria (grad 3 = G3; grad 3-4 = G3/4; grad 4 = G4) og COSTART-termerne og MedDRA-termerne.
These reactions were described using the NCI Common Toxicity Criteria (grade 3 = G3; grade 3-4 = G3/4; grade 4 = G4) and the COSTART and the MedDRA terms.
Disse reaktioner blev generelt observeret på infusionsdagen, men akutte overfølsomhedsreaktioner kan også opstå dagen efter infusionen.
These reactions were generally observed on the day of infusion, but acute hypersensitivity reactions may also occur on the day after dosing.
Disse reaktioner blev observeret mindre hyppigt hos antistof-negative patienter (4 %) sammenlignet med de antistof-positive patienter (13 %) og med øget forekomst hos patienter med højere antistoftitre.
These reactions were less commonly observed in antibody-negative patients (4 %) compared with antibody-positive patients (13 %), with a greater incidence in those with higher titre antibodies.
Disse reaktioner bør forsvinde inden for 2-3 dage.
These reactions should disappear within 2-3 days.
Disse reaktioner er af varierende form, men typisk ses feber og udslæt, og forskellige organsystemer kan inddrages.
These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems.
Disse reaktioner er almindeligvis midlertidige og forsvinder, når behandlingen ophører.
These reactions are generally temporary and reversible when the treatment is stopped.
Disse reaktioner er ikke kumulative, men er typisk reversible og fører sædvanligvis ikke til seponering.
The above reactions were not cumulative, were typically reversible and generally did not result in treatment discontinuation.
Disse reaktioner er ikke set i de kliniske studier med Coagadex.
These reactions have not been reported during clinical studies with Coagadex.
Disse reaktioner er ikke set med HyQvia, men der er en lille mulighed for, at en person, der får HyQvia, kan få dem:
These reactions have not been seen with HyQvia, but there is a small possibility that someone using HyQvia may get them:
Disse reaktioner er meget almindelige (kan forekomme hos flere end 1 ud af 10 patienter).
These reactions are very common (may affect more than 1 in 10 people)
Disse reaktioner er sædvanligvis forbigående og vil normalt forsvinde ved fortsat behandling.
Most reactions are transitory and disappear during continued treatment.
Disse reaktioner forekommer med større sandsynlighed på dagen eller dagen efter din første eller din anden behandling med Benlysta.
These reactions are more likely to happen on the day of, or day after, your first or second treatment with Benlysta.
Disse reaktioner forsvandt som regel inden for 1-2 dage efter vaccinationen.
These reactions usually disappeared within 1-2 days without treatment.
Disse reaktioner forsvinder eller mindskes betydeligt ved kontinuerlig brug og kan bedres ved egnet behandling med beta2-agonister før eller efterfølgende inhalation af colisthimetatnatrium-tørpulver.
These reactions usually disappear or significantly diminish with continued use and may be ameliorated by appropriate treatment with beta2- agonists prior to or following dry powder colistimethate sodium inhalation.
Disse reaktioner heler spontant inden for højst 4 dage i gennemsnit uden nogen følger for sundheden og zooteknisk adfærd hos søer, polte og gylte.
These reactions resolve spontaneously, in a maximum of 4 days on average, without any consequence on the health and the zootechnical performance.
Disse reaktioner kan blive mere alvorlige, eller måske ændre optagelsen af nsulinet, hvis du injicerer på et sådant sted.
These reactions can become more severe, or they may change the absorption of your insulin, if you inject in such a site.
Disse reaktioner kan opstå i løbet af den første uge, hvor du får behandlingen, men varer som regel kun i op til 7 dage.
These reactions can appear in the first week of treatment and usually only last for up to 7 days.
Disse reaktioner kan optræde, inden du forlader lægens klinik.
Such reactions may occur before leaving the doctor’s surgery.
Disse reaktioner kan variere fra milde til alvorlige og kan omfatte en pludseligt opstået overfølsomhedsreaktion i hele kroppen, hvilket kan føre til livstruende shock (dvs. besvær med vejrtrækningen, blodtryksfald, hurtig puls)
Anaphylaxis/anaphylactoid reactions (that may range from mild to severe, including a sudden, generalised allergic reaction that may lead to a life-threatening shock [e.g. difficulty in breathing, drop of blood pressure, fast pulse]).
Disse reaktioner omfatter rødme, smerter, kløe, udslæt, hævelse eller inflammation.
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Disse reaktioner omfatter:
These reactions include;
Disse reaktioner var for det meste moderate (mindre end eller lig med 39°C) og forbigående (se afsnit 4.8).
These reactions were mostly moderate (less than or equal to 39 °C) and transient (see section 4.8).
Disse reaktioner var for størstedelens vedkommende moderate ( 39°C) og forbigående.
These reactions were mostly moderate (less than or equal to 39° C) and transient.
Disse reaktioner var generelt lette og førte normalt ikke til udtrædelse af studierne.
These injection site reactions were generally mild and usually did not lead to withdrawal from studies.
Disse reaktioner var mere almindelige hos patienter med baseline eGRF ≥ 30 og < 60 ml/min/1,73m2 (18,5 % dapagliflozin 10 mg versus 9,3 % placebo).
These reactions were more common in patients with baseline eGFR ≥ 30 and < 60 mL/min/1.73m2 (18.5% dapagliflozin 10 mg vs 9.3% placebo).
Disse reaktioner var primært af forbigående art.
These reactions were primarily transient in nature.
Disse reaktioner ved injektionsstedet (inklusive erythem, pruritus, smerter og hæmatom) varaf ilet til moderat i sværhedsgrad.
These injection site reactions (including erythema, pruritus, pain and haematoma) were mild to moderate in severity.
Disse reaktioner vil forsvinde indenfor maksimalt 23 dage.
These reactions will resolve within a maximum of 23 days.
Disse reaktioner vil normalt forekomme, inden du forlader lægen.
These reactions will usually occur before leaving the doctor’s surgery.
Disse receptorer er en del af i en naturlig mekanisme i kroppen, som kan få arterier til at trække sig sammen.
These are part of a natural mechanism in the body that can cause arteries to narrow.
Disse receptorer findes også i mavetarmkanalen.
These receptors are also found in the gut.
Disse receptorer kontrollerer blodets indhold af kolesterol, navnlig LDL- kolesterol, ved at fjerne det fra blodbanen.
These receptors control blood levels of cholesterol, especially LDL-cholesterol, by removing it from the bloodstream.
Disse receptorer kontrollerer cholesterolniveauerne i blodet, specielt LDL- cholesterol, ved at fjerne det fra blodbanen.
These receptors control blood levels of cholesterol, especially LDL- cholesterol, by removing it from the blood stream.
Disse receptorer udløser produktionen af spyt, når de aktiveres af nerver, der
These receptors trigger the production of saliva when activated by nerves from the brain.
Disse reduktioner blev anset for at have klinisk betydning.
12.5 mg dose, and these reductions were considered clinically relevant.
Disse reduktioner udgør en procentvis reduktion på 56 % vs.
These reductions represent a percentage reduction of 56% vs.
Disse resultater antyder, at unge dyr mangler fuldt udviklede metaboliseringsveje, der gør dem i stand til at udskille amprenavir eller nogle kritiske bestanddele af formuleringen (f.eks. propylenglycol, PEG 400).
These results imply that young animals lack fully developed metabolic pathways enabling them to excrete amprenavir or some critical components of the formulation (e.g. propylene glycol, PEG400).
Disse resultater blev bekræftet i en sensitivitetsanalyse, hvor overfladiskneovaskularisering blev evalueret af en uafhængig sagkyndig fra blindede fotografier af patientens øjne taget før og efter Holoclar- implantationen.
These results were confirmed in a sensitivity analysis where superficial neovascularisation was evaluated by an independent assessor from blinded photos of patients’ eyes taken before and after Holoclar implantation.